Published in J Clin Invest on June 01, 1994
Activation of human endothelial cells by viable or heat-killed gram-negative bacteria requires soluble CD14. Infect Immun (1995) 1.15
Urokinase receptor is a multifunctional protein: influence of receptor occupancy on macrophage gene expression. J Clin Invest (1995) 1.08
An uncleaved glycosylphosphatidylinositol signal mediates Ca(2+)-sensitive protein degradation. Biochem J (1996) 0.75
Cell-surface anchoring of proteins via glycosyl-phosphatidylinositol structures. Annu Rev Biochem (1988) 7.57
Structural and functional roles of glycosyl-phosphatidylinositol in membranes. Science (1988) 5.36
Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell (1993) 4.04
Glycolipid anchoring of plasma membrane proteins. Annu Rev Cell Biol (1990) 3.88
Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med (1986) 3.68
The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors. Annu Rev Biochem (1993) 3.65
Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1983) 3.47
Polarized apical distribution of glycosyl-phosphatidylinositol-anchored proteins in a renal epithelial cell line. Proc Natl Acad Sci U S A (1988) 3.19
The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science (1993) 2.77
The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature (1988) 2.66
STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT. J Clin Invest (1939) 2.55
Cloning and sequencing of the yeast gene for dolichol phosphate mannose synthase, an essential protein. J Biol Chem (1988) 2.52
Glycosyl-phosphatidylinositol: a versatile anchor for cell surface proteins. FASEB J (1989) 2.31
Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med (1994) 2.27
The biological chemistry of folate receptors. Blood (1992) 2.27
Lipid analysis of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase. Palmitoylation of inositol results in resistance to phosphatidylinositol-specific phospholipase C. J Biol Chem (1988) 2.18
Complete structure of the glycosyl phosphatidylinositol membrane anchor of rat brain Thy-1 glycoprotein. Nature (1988) 2.17
Monocyte antigen CD14 is a phospholipid anchored membrane protein. Blood (1989) 2.10
Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 2.01
A platelet and granulocyte membrane defect in paroxysmal nocturnal hemoglobinuria: usefulness for the detection of platelet antibodies. J Clin Invest (1969) 1.91
Studies on phosphatidylinositol phosphodiesterase (phospholipase C type) of Bacillus cereus. I. purification, properties and phosphatase-releasing activity. Biochim Biophys Acta (1976) 1.83
Paroxysmal nocturnal haemoglobinuria (PNH) is caused by somatic mutations in the PIG-A gene. EMBO J (1994) 1.80
Structural characterization of the glycoinositol phospholipid membrane anchor of human erythrocyte acetylcholinesterase by fast atom bombardment mass spectrometry. J Biol Chem (1988) 1.79
Paroxysmal nocturnal haemoglobinuria. Clin Haematol (1985) 1.55
Release of alkaline phosphatase from membranes by a phosphatidylinositol-specific phospholipase C. Biochem J (1977) 1.50
Characterization of putative glycoinositol phospholipid anchor precursors in mammalian cells. Localization of phosphoethanolamine. J Biol Chem (1992) 1.49
Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med (1987) 1.44
Early lipid intermediates in glycosyl-phosphatidylinositol anchor assembly are synthesized in the ER and located in the cytoplasmic leaflet of the ER membrane bilayer. J Cell Biol (1993) 1.43
Identification of defects in glycosylphosphatidylinositol anchor biosynthesis in the Thy-1 expression mutants. J Biol Chem (1991) 1.41
Inositol acylation of a potential glycosyl phosphoinositol anchor precursor from yeast requires acyl coenzyme A. J Biol Chem (1992) 1.39
Phosphatidylinositol-linked proteins and paroxysmal nocturnal hemoglobinuria. Blood (1990) 1.38
TAP transcription and phosphatidylinositol linkage mutants are defective in activation through the T cell receptor. Cell (1988) 1.36
The kidneys in paroxysmal nocturnal hemoglobinuria. Blood (1981) 1.34
Defective glycosyl phosphatidylinositol biosynthesis in extracts of three Thy-1 negative lymphoma cell mutants. J Biol Chem (1991) 1.28
Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor. J Exp Med (1987) 1.27
Primary structure of human placental 5'-nucleotidase and identification of the glycolipid anchor in the mature form. Eur J Biochem (1990) 1.26
Correction of the class H defect in glycosylphosphatidylinositol anchor biosynthesis in Ltk- cells by a human cDNA clone. J Biol Chem (1993) 1.20
Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1987) 1.18
Affected paroxysmal nocturnal hemoglobinuria T lymphocytes harbor a common defect in assembly of N-acetyl-D-glucosamine inositol phospholipid corresponding to that in class A Thy-1- murine lymphoma mutants. J Biol Chem (1992) 1.17
Paroxysmal nocturnal hemoglobinuria type III. Lack of an erythrocyte membrane protein restricting the lysis by C5b-9. J Clin Invest (1987) 1.16
Phosphatidylethanolamine is the donor of the ethanolamine residue linking a glycosylphosphatidylinositol anchor to protein. J Biol Chem (1992) 1.15
Characterization of glycophospholipid intermediate in the biosynthesis of glycophosphatidylinositol anchors accumulating in the Thy-1-negative lymphoma line SIA-b. J Biol Chem (1991) 1.15
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood (1993) 1.13
Identification of a missing link in glycosylphosphatidylinositol anchor biosynthesis in mammalian cells. J Biol Chem (1992) 1.13
Correction of a defect in mammalian GPI anchor biosynthesis by a transfected yeast gene. Science (1990) 1.11
Characterization of abnormal free glycophosphatidylinositols accumulating in mutant lymphoma cells of classes B, E, F, and H. J Biol Chem (1993) 1.11
Somatic genetic analysis of the expression of cell surface molecules. Trends Genet (1988) 1.11
Specific defect in N-acetylglucosamine incorporation in the biosynthesis of the glycosylphosphatidylinositol anchor in cloned cell lines from patients with paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A (1993) 1.11
Paroxysmal nocturnal haemoglobinuria: variation in clinical severity and association with bone-marrow hypoplasia. Br J Haematol (1961) 1.09
Phosphatidylethanolamine is the donor of the terminal phosphoethanolamine group in trypanosome glycosylphosphatidylinositols. EMBO J (1993) 1.09
Biochemical studies on leucocytes. II. Phosphatase activity in chronic lymphatic leucemia, acute leucemia, and miscellaneous hematologic conditions. J Lab Clin Med (1951) 1.09
Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 1.07
The population of cells in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis: significance and mechanism of increased immune lysis. Br J Haematol (1974) 1.05
Complexity of ethanolamine phosphate addition in the biosynthesis of glycosylphosphatidylinositol anchors in mammalian cells. J Biol Chem (1992) 1.04
Cloning of a human gene, PIG-F, a component of glycosylphosphatidylinositol anchor biosynthesis, by a novel expression cloning strategy. J Biol Chem (1993) 1.04
The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria. Blood (1992) 1.03
Diagnosis of paroxysmal nocturnal haemoglobinuria using immunophenotyping of peripheral blood cells. Br J Haematol (1991) 1.02
Structural requirements of a nascent protein for processing to a PI-G anchored form: studies in intact cells and cell-free systems. Cell Biol Int Rep (1991) 1.01
Regulation of glycosylphosphatidylinositol biosynthesis by GTP. Stimulation of N-acetylglucosamine-phosphatidylinositol deacetylation. J Biol Chem (1993) 1.01
Biosynthesis of phosphatidylinositol-glycan (PI-G)-anchored membrane proteins in cell-free systems: PI-G is an obligatory cosubstrate for COOH-terminal processing of nascent proteins. Proc Natl Acad Sci U S A (1992) 0.96
Erythrocyte acetylcholinesterase deficiency in paroxysmal nocturnal hemoglobinuria (PNH). A comparison of the complement-sensitive and insensitive populations. Blood (1969) 0.95
The erythrocyte acetylcholinesterase enzyme in paroxysmal nocturnal hemoglobinuria. Arch Pathol (1960) 0.94
Neutrophil (leucocyte) alkaline phosphatase in paroxysmal nocturnal haemoglobinuria. Br J Haematol (1965) 0.93
Urinary iron excretion and renal metabolism of hemoglobin in hemolytic diseases. Blood (1966) 0.91
Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood (1992) 0.88
Glycosyl-phosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria: partial or complete defect in an early step. Blood (1994) 0.87
The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis. Br J Haematol (1991) 0.85
Antibody By114 is selective for the 90 kD PI-linked component of the CD66 antigen: a new reagent for the study of paroxysmal nocturnal haemoglobinuria. Br J Haematol (1993) 0.84
Preferential expression of human Fc gamma RIIIPMN (CD16) in paroxysmal nocturnal hemoglobinuria. Discordant expression of glycosyl phosphatidylinositol-linked proteins. J Clin Invest (1991) 0.82
Differential expression of glycosylphosphatidylinositol-anchored proteins in a murine T cell hybridoma mutant producing limiting amounts of the glycolipid core. Implications for paroxysmal nocturnal hemoglobinuria. J Clin Invest (1992) 0.79
A deficiency in CDw52 (CAMPATH-1 antigen) of paroxysmal nocturnal hemoglobinuria lymphocytes. Blood (1993) 0.78
Isolation of the JMH antigen on a novel phosphatidylinositol-linked human membrane protein. Blood (1992) 0.77
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med (1994) 15.82
Pain in sickle cell disease. Rates and risk factors. N Engl J Med (1991) 9.75
The major Fc receptor in blood has a phosphatidylinositol anchor and is deficient in paroxysmal nocturnal haemoglobinuria. Nature (1988) 2.66
Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest (1966) 2.58
The cooperative study of sickle cell disease: review of study design and objectives. Am J Pediatr Hematol Oncol (1982) 1.85
Morphologic changes in the membranes of red blood cells undergoing hemolysis. Am J Med (1966) 1.70
Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. 3. The membrane defects caused by complement lysis. J Exp Med (1966) 1.57
Paroxysmal nocturnal haemoglobinuria. Clin Haematol (1985) 1.55
Familial cold urticaria. A generalized reaction involving leukocytosis. Arch Intern Med (1969) 1.53
Splenectomy for primary and recurrent immune thrombocytopenic purpura (ITP). Current criteria for patient selection and results. Ann Surg (1987) 1.37
The use of monoclonal antibodies and flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria. Blood (1996) 1.34
Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1982) 1.32
Acquired DNA mutations associated with in vivo hydroxyurea exposure. Blood (2000) 1.29
Mechanisms of immune lysis of red blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest (1973) 1.29
Platelet antibody in autoimmune thrombocytopenia. Br J Haematol (1975) 1.27
Mechanisms of immune lysis of the red cells in hereditary erythroblastic multinuclearity with a positive acidified serum test and paroxysmal nocturnal hemoglobinuria. J Clin Invest (1974) 1.24
Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol (1973) 1.24
Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes. J Immunol (1983) 1.20
Chlorpropamide-induced immune hemolytic anemia. N Engl J Med (1970) 1.20
Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1987) 1.18
Quantitative influence of antibody and complement coating of red cells on monocyte-mediated cell lysis. J Clin Invest (1978) 1.18
Fixation of the first component of complement (C'la) by human antibodies. J Clin Invest (1969) 1.17
Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells. Proc Natl Acad Sci U S A (1988) 1.14
Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria. Blood (1993) 1.13
Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood (1990) 1.13
Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1985) 1.12
Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysis. J Clin Invest (1966) 1.11
Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome. J Clin Invest (1973) 1.10
The lysis of paroxysmal nocturnal haemoglobinuria red cells by serum and cobra factor. Br J Haematol (1972) 1.10
Characterization of the IgG-Fc receptor on human platelets. Blood (1982) 1.09
Immune thrombocytopenia in lymphoproliferative diseases. Blood (1979) 1.08
The variability of hemolysis in the cold agglutinin syndrome. Blood (1980) 1.08
Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF. J Exp Med (1988) 1.07
Abnormality of glycophorin-alpha on paroxysmal nocturnal hemoglobinuria erythrocytes. J Clin Invest (1984) 1.07
Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest (1989) 1.07
Mechanism of complement-mediated activation of human blood platelets in vitro: comparison of normal and paroxysmal nocturnal hemoglobinuria platelets. J Clin Invest (1977) 1.07
Reaction of cold agglutinins with I antigen solubilized from human red cells. Blood (1970) 1.06
The population of cells in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis: significance and mechanism of increased immune lysis. Br J Haematol (1974) 1.05
Further evidence for location of the spherocytosis gene on chromosome 8. Ann Intern Med (1983) 1.04
Two populations of granulocytes in paroxysmal nocturnal hemoglobinuria. Blood (1979) 1.03
The use of in vitro technics to study drug-induced pancytopenia. N Engl J Med (1979) 1.01
The acetylcholinesterase defect in paroxysmal nocturnal hemoglobinuria: evidence that the enzyme is absent from the cell membrane. Blood (1985) 1.01
The structure of the urokinase-type plasminogen activator receptor gene. Blood (1994) 0.99
Mutations within the Piga gene in patients with paroxysmal nocturnal hemoglobinuria. Blood (1994) 0.99
Production of IgM hexamers by normal and autoimmune B cells: implications for the physiologic role of hexameric IgM. J Immunol (1998) 0.99
Fragment D-dimer levels: an objective marker of vaso-occlusive crisis and other complications of sickle cell disease. Blood (1986) 0.98
The response of human neutrophils to a chemotactic tripeptide (N-formyl-methionyl-leucyl-phenylalanine) studied by microcinematography. Blood (1984) 0.97
Cold-reacting antibodies: differences in the reaction of anti-I antibodies with adult and cord red blood cells. Blood (1970) 0.97
Separation of the acetylcholinesterase-deficient red cells in paroxysmal nocturnal hemoglobinuria. Blood (1986) 0.96
Cold-reacting antibodies: the enhancement of antibody fixation by the first component of complement (C'1a). J Immunol (1968) 0.96
Erythrocyte acetylcholinesterase deficiency in paroxysmal nocturnal hemoglobinuria (PNH). A comparison of the complement-sensitive and insensitive populations. Blood (1969) 0.95
Paroxysmal nocturnal haemoglobinuria in aplastic anaemia. Clin Haematol (1978) 0.94
Quantitative immunology of immune hemolytic anemia. I. The fixation of C1 by autoimmune antibody and heterologous anti-IgG antibody. J Clin Invest (1971) 0.94
The spleen as a filter. N Engl J Med (1987) 0.94
Structure of the CD59-encoding gene: further evidence of a relationship to murine lymphocyte antigen Ly-6 protein. Proc Natl Acad Sci U S A (1992) 0.94
The life-span of complement-sensitive and -insensitive red cells in paroxysmal nocturnal hemoglobinuria. Blood (1971) 0.94
Differences in the terminal steps of complement lysis of normal and paroxysmal nocturnal hemoglobinuria red cells. Blood (1978) 0.94
Structure-function relationships of the complement regulatory protein, CD59. Blood Cells Mol Dis (1996) 0.94
Inhibitors of complement derived from the erythrocyte membrane in paroxysmal nocturnal hemoglobinuria. Blood (1980) 0.93
Platelet-bound complement (C3) in immune thrombocytopenia. Blood (1977) 0.93
The reactivity of red blood cell membrane glycophorin with "cold-reacting" antibodies. Clin Immunol Immunopathol (1975) 0.91
The control of complement activation by the blood cells in paroxysmal nocturnal hemoglobinuria. Blood (1986) 0.91
Complement-dependent immune adherence measured with human granulocytes: changes in the antigenic nature of red cell-bound C3 produced by incubation in human serum. Clin Immunol Immunopathol (1973) 0.91
Intravenous immunoglobulin administration in the treatment of severe chronic immune thrombocytopenic purpura. Am J Med (1984) 0.90
Treatment of paroxysmal nocturnal hemoglobinuria. Blood (1982) 0.90
Pseudo-Bernard-Soulier syndrome: thrombocytopenia caused by autoantibody to platelet glycoprotein Ib. Blood (1987) 0.89
Red-cell abnormalities in HEMPAS (hereditary erythroblastic multinuclearity with a positive acidified-serum test). Br J Haematol (1972) 0.89
Paroxysmal nocturnal hemoglobinuria--present status and future prospects. West J Med (1980) 0.89
The PIG-A mutation and absence of glycosylphosphatidylinositol-linked proteins do not confer resistance to apoptosis in paroxysmal nocturnal hemoglobinuria. Blood (1998) 0.88
Successful treatment of hepatitis C in sickle-cell disease. Ann Intern Med (2000) 0.88
Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H. Proc Natl Acad Sci U S A (1987) 0.88
Distinct restriction of complement- and cell-mediated lysis. J Immunol (1989) 0.88
The complement sensitivity on PNH cells. Ser Haematol (1972) 0.88
Structural characteristics of hemolytic antibodies as determined by the effects of ionizing radiation. J Immunol (1967) 0.88
Defective glycosylphosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria granulocytes. Blood (1992) 0.88
Glycosyl-phosphatidylinositol anchor synthesis in paroxysmal nocturnal hemoglobinuria: partial or complete defect in an early step. Blood (1994) 0.87
Dr Ham's test revisited. Blood (1991) 0.86
Recurrent thrombocytopenia following idiopathic thrombocytopenic purpura. The importance of platelet-bound IgG in establishing cause. Arch Intern Med (1980) 0.86
Pulmonary embolism and splenic infarction in a patient with sickle cell trait. Am J Hematol (1990) 0.85
Resolution of Budd-Chiari syndrome following bone marrow transplantation for paroxysmal nocturnal haemoglobinuria. Br J Haematol (1996) 0.85
Reactions of immunoglobulin G-binding ligands with platelets and platelet-associated immunoglobulin G. J Clin Invest (1984) 0.84
Factors controlling erythropoiesis in birds. Blood (1966) 0.84
Genetic instability and the etiology of somatic PIG-A mutations in paroxysmal nocturnal hemoglobinuria. Blood Cells Mol Dis (1999) 0.83
Immunophenotypic analysis of reticulocytes in paroxysmal nocturnal hemoglobinuria. Blood (1995) 0.83
The erythropoiesis-stimulating factors produced by tumors. Ann N Y Acad Sci (1968) 0.82
Presence of P blood group antigens on human platelets. Am J Clin Pathol (1985) 0.82
Complement sensitivity of paroxysmal nocturnal hemoglobinuria bone marrow cells. Blood (1980) 0.82
Refocusing on history-taking skills during internal medicine training. Am J Med (1996) 0.82
Paroxysmal nocturnal hemoglobinuria with onset in childhood and adolescence. N Engl J Med (1991) 0.82
The effect of iron therapy in paroxysmal nocturnal hemoglobinuria. Blood (1970) 0.81
The autinglobulin test in autoimmune hemolytic anemia. Annu Rev Med (1975) 0.81
Congential dyserythropoietic anemia--type IV. J Pediatr (1975) 0.81
Potassium permeability in -thalassemia minor red blood cells. J Clin Invest (1972) 0.81
Selective chemotherapy of macrophages in the treatment of idiopathic thrombocytopenic purpura. N Engl J Med (1978) 0.81
The origin of ABH antigens on human platelets. Blood (1985) 0.81
Treatment of chronic immune thrombocytopenia. Clin Haematol (1983) 0.81
Monocyte-mediated destruction in the presence of serum of red cells coated with antibody. Blood (1979) 0.81
Prognostic implications for direct platelet-associated IgG in childhood idiopathic thrombocytopenic purpura. Am J Pediatr Hematol Oncol (1986) 0.80
Endogenous carbon monoxide production measured by gas-phase analysis: an estimation of heme catabolic rate. J Lab Clin Med (1971) 0.80
Immunologic studies before and after splenectomy in a patient with the Wiskott-Aldrich syndrome. J Clin Immunol (1981) 0.80